| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.0094 | 0.9 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.009 | 0.9 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.008 | 0.9 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.9 |